Abstract
A new approach to the treatment of angina pectoris has been introduced, which uses propranolol, a β-adrenergic receptor blockading agent. Effects are based primarily on prevention of sympathetically induced increases in cardiac work rather than on coronary vasodilatation. Initial clinical reports indicate that propranolol-treated patients may require less nitroglycerine and may have improved exercise tolerance. Long-term efficacy has not been demonstrated. No evidence exists that electrocardiographic improvement has occurred, nor that there is greater longevity in anginal patients who have followed long-term propranolol therapy. Further clinical information is necessary in order to determine the ultimate role of propranolol or other β-adrenergic-blockading agents in the treatment of angina pectoris.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
